0001683168-23-008694 | 10-Q | XBRL Viewer

Print Document View Excel Document

Summary of Significant Accounting Policies (Details - Revenue) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Product Information [Line Items]
Revenues	$ 25,395	$ 34,757	$ 63,121	$ 71,449
Manufacturing Revenue [Member]
Product Information [Line Items]
Revenues	20,128	27,614	53,548	59,095
Process Development Revenue [Member]
Product Information [Line Items]
Revenues	$ 5,267	$ 7,143	$ 9,573	$ 12,354

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Net Income (Loss) Per Common Share

6 Months Ended

Oct. 31, 2023

Net income (loss) per share:

Net Income (Loss) Per Common Share

Note 8 – Net Income (Loss) Per Common Share

Basic net income (loss) per common share is computed by dividing our net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing our net income (loss) by the sum of the weighted average number of shares of common stock outstanding during the period plus the potential dilutive effects of stock options, unvested RSUs, unvested PSUs, shares of common stock expected to be issued under our ESPP, and Convertible Notes.

The potential dilutive effect of stock options, unvested RSUs, unvested PSUs, and shares of common stock expected to be issued under our ESPP during the period are calculated in accordance with the treasury stock method but are excluded if their effect is anti-dilutive. The potential dilutive effect of our Convertible Notes is calculated using the if-converted method assuming the conversion of our Convertible Notes as of the earliest period reported or at the date of issuance, if later, but are excluded if their effect is anti-dilutive. A reconciliation of the numerators and the denominators of the basic and dilutive net income (loss) per common share computations are as follows (in thousands, except per share amounts):


	Three Months Ended October 31,						Six Months Ended October 31,
	2023			2022			2023			2022
Numerator
Net income (loss)	$	(9,509	)	$	(1,156	)	$	(11,602	)	$	408
Denominator
Weighted average basic common shares outstanding		63,149			62,204			62,994			62,054
Effect of dilutive securities:
Stock options		–			–			–			1,294
RSUs, PSUs and ESPP		–			–			–			226
Weighted average dilutive common shares outstanding		63,149			62,204			62,994			63,574
Net income (loss) per share:
Basic	$	(0.15	)	$	(0.02	)	$	(0.18	)	$	0.01
Diluted	$	(0.15	)	$	(0.02	)	$	(0.18	)	$	0.01

The following table presents the potential dilutive securities excluded from the calculation of diluted net income (loss) per share for the periods presented as the effect of their inclusion would have been anti-dilutive (in thousands):

Schedule of antidilutive shares
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Stock options		877		1,404		962		51
RSUs, PSUs and ESPP		1,400		433		1,241		640
Convertible Notes		6,776		6,776		6,776		6,776
Total		9,053		8,613		8,979		7,467

Equity Compensation Plans (Details - PSU Activity) - Performance Stock Units [Member] shares in Thousands	6 Months Ended
	Oct. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding beginning balance \| shares	522
Weighted average grant date fair value, Outstanding beginning balance \| $ / shares	$ 19.70
PSUs shares, Granted \| shares	613
PSUs weighted average grant date fair value, Granted \| $ / shares	$ 13.92
PSUs shares, Vested \| shares	0
PSUs weighted average grant date fair value, Vested \| $ / shares	$ 0
PSUs shares, Forfeited \| shares	0
PSUs weighted average grant date fair value, Forfeited \| $ / shares	$ 0
Outstanding ending balance \| shares	1,135
Weighted average grant date fair value, Outstanding ending balance \| $ / shares	$ 16.58

Income Taxes	6 Months Ended
Oct. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 – Income Taxes We are subject to taxation in the United States and various states jurisdictions in which we conduct our business. Our tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items arising in that quarter. On a quarterly basis, we update our estimate of the annual effective tax rate, and if the estimated annual tax rate changes, we make a cumulative adjustment in that quarter. The provision for income taxes recorded for the three and six months ended October 31, 2023 and 2022 differs from the U.S. federal statutory tax rate of 21% due primarily to the tax impact of stock-based compensation, non-deductible officers’ compensation, and transportation fringe benefits. For the three and six months ended October 31, 2023, we recorded an income tax (benefit) of $(2.4) million $(3.0) million, respectively, resulting in an effective tax rate of approximately 20.0% and 20.4%, respectively. For the three and six months ended October 31, 2022, we recorded an income tax (benefit) of $(2.1) million and $(1.4) million, respectively, resulting in an effective tax rate of 64.3% and 141.8%, respectively. We have no material uncertain tax position liabilities as of October 31, 2023 and April 30, 2023. It is our policy to recognize interest and penalties related to income tax matters in interest expense and other income (expense), net, respectively, in our unaudited condensed consolidated statements of income (loss) and comprehensive income (loss). There was no accrued interest or penalties associated with uncertain tax positions as of October 31, 2023 and April 30, 2023.

Income Taxes

6 Months Ended

Oct. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Note 7 – Income Taxes

We are subject to taxation in the United States and various states jurisdictions in which we conduct our business.

Our tax provision for interim periods is determined using an estimate of our annual effective tax rate, adjusted for discrete items arising in that quarter. On a quarterly basis, we update our estimate of the annual effective tax rate, and if the estimated annual tax rate changes, we make a cumulative adjustment in that quarter.

The provision for income taxes recorded for the three and six months ended October 31, 2023 and 2022 differs from the U.S. federal statutory tax rate of 21% due primarily to the tax impact of stock-based compensation, non-deductible officers’ compensation, and transportation fringe benefits.

For the three and six months ended October 31, 2023, we recorded an income tax (benefit) of $(2.4) million $(3.0) million, respectively, resulting in an effective tax rate of approximately 20.0% and 20.4%, respectively. For the three and six months ended October 31, 2022, we recorded an income tax (benefit) of $(2.1) million and $(1.4) million, respectively, resulting in an effective tax rate of 64.3% and 141.8%, respectively.

We have no material uncertain tax position liabilities as of October 31, 2023 and April 30, 2023. It is our policy to recognize interest and penalties related to income tax matters in interest expense and other income (expense), net, respectively, in our unaudited condensed consolidated statements of income (loss) and comprehensive income (loss). There was no accrued interest or penalties associated with uncertain tax positions as of October 31, 2023 and April 30, 2023.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Description of Company and Basis of Presentation	6 Months Ended
Oct. 31, 2023
Accounting Policies [Abstract]
Description of Company and Basis of Presentation	Note 1 – Description of Company and Basis of Presentation We are a dedicated contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of services from process development to Current Good Manufacturing Practices (“CGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to quarterly reports on Form 10-Q, and accordingly, they do not include all the information and disclosures required by U.S. GAAP for annual financial statements. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended April 30, 2023, as filed with the SEC on June 21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Results of operations for interim periods covered by this Quarterly Report on Form 10-Q may not necessarily be indicative of results of operations for the full fiscal year or any other interim period. The unaudited condensed consolidated financial statements include the accounts of Avid Bioservices, Inc. and its subsidiary. All intercompany accounts and transactions among the consolidated entities have been eliminated in the unaudited condensed consolidated financial statements. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts, as well as disclosures of commitments and contingencies in the financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.

Description of Company and Basis of Presentation

6 Months Ended

Oct. 31, 2023

Accounting Policies [Abstract]

Description of Company and Basis of Presentation

Note 1 – Description of Company and Basis of Presentation

We are a dedicated contract development and manufacturing organization (“CDMO”) that provides a comprehensive range of services from process development to Current Good Manufacturing Practices (“CGMP”) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) related to quarterly reports on Form 10-Q, and accordingly, they do not include all the information and disclosures required by U.S. GAAP for annual financial statements. These unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended April 30, 2023, as filed with the SEC on June 21, 2023. The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operations for the periods presented, with such adjustments consisting only of normal recurring adjustments. Results of operations for interim periods covered by this Quarterly Report on Form 10-Q may not necessarily be indicative of results of operations for the full fiscal year or any other interim period.

The unaudited condensed consolidated financial statements include the accounts of Avid Bioservices, Inc. and its subsidiary. All intercompany accounts and transactions among the consolidated entities have been eliminated in the unaudited condensed consolidated financial statements.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts, as well as disclosures of commitments and contingencies in the financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Oct. 31, 2023

Accounting Policies [Abstract]

Schedule of revenues

Schedule of revenues
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Manufacturing revenues	$	20,128	$	27,614	$	53,548	$	59,095
Process development revenues		5,267		7,143		9,573		12,354
Total revenues	$	25,395	$	34,757	$	63,121	$	71,449

Schedule of cash

Schedule of cash
	October 31, 2023		April 30, 2023		October 31, 2022		April 30, 2022
Cash and cash equivalents	$	31,424	$	38,542	$	77,292	$	126,166
Restricted cash		–		350		350		350
Total cash, cash equivalents and restricted cash	$	31,424	$	38,892	$	77,642	$	126,516

Schedule of estimated useful lives of property


Description		Estimated Useful Life
Leasehold improvements		Shorter of estimated useful life or lease term
Laboratory and manufacturing equipment		5 – 15 years
Computer equipment and software		3 – 5 years
Furniture, fixtures and office equipment		5 – 10 years

Schedule of property and equipment

Schedule of property and equipment
	October 31, 2023			April 30, 2023
Leasehold improvements	$	101,310		$	97,514
Laboratory and manufacturing equipment		43,336			35,501
Computer equipment and software		5,170			5,028
Furniture, fixtures and office equipment		1,910			1,681
Construction-in-progress		71,124			68,013
Total property and equipment, gross		222,850			207,737
Less: accumulated depreciation and amortization		(35,676	)		(30,368	)
Total property and equipment, net	$	187,174		$	177,369

Leases (Details - Operating and finance leases)	Oct. 31, 2023	Apr. 30, 2023
Leases
Weighted average remaining lease term, operating leases	16 years 2 months 12 days	16 years 7 months 6 days
Weighted average remaining lease term, finance lease	6 years 2 months 12 days	3 years 8 months 12 days
Weighted average discount rate, operating leases	6.00%	6.00%
Weighted average discount rate, finance lease	6.40%	5.30%

Equity Compensation Plans

6 Months Ended

Oct. 31, 2023

Share-Based Payment Arrangement [Abstract]

Equity Compensation Plans

Note 5 – Equity Compensation Plans

Stock Incentive Plans

As of October 31, 2023, we had an aggregate of 7,682,971 shares of our common stock reserved for issuance under our stock incentive plans, of which 4,501,434 shares were subject to outstanding stock options, restricted stock units (“RSUs”) and performance stock units (“PSUs”) and 3,181,537 shares were available for future grants of stock-based awards.

Stock Options

The following summarizes our stock option transaction activity for the six months ended October 31, 2023:

Schedule of stock option activity
	Stock Options		Grant Date Weighted Average Exercise Price
		(in thousands)
Outstanding at May 1, 2023		2,079		$6.76
Granted		–		$–
Exercised		(62)		$7.65
Canceled or expired		(16)		$11.99
Outstanding at October 31, 2023		2,001		$6.69

Restricted Stock Units

The following summarizes our RSUs transaction activity for the six months ended October 31, 2023:

Schedule of RSU activity
	Shares		Weighted Average Grant Date Fair Value
		(in thousands)
Outstanding at May 1, 2023		1,006		$16.83
Granted		673		$14.00
Vested		(274)		$13.73
Forfeited		(40)		$16.98
Outstanding at October 31, 2023		1,365		$16.05

Performance Stock Units

The Compensation Committee of the Board of Directors grants PSUs to our executives. The PSUs are subject to annual vesting over three consecutive fiscal year performance periods with the first one-third vesting on April 30 of the year following the grant date, and each successive one-third vesting on April 30 of the following two years respectively (each a “Performance Period”). Each PSU that vests represent the right to receive one share of our common stock. The number of shares that will vest for each Performance Period, if any, is based upon the attainment of certain predetermined financial metrics for each such Performance Period. Depending on the actual financial metrics achieved relative to the target financial metrics for such Performance Periods, the number of PSUs issued could range from 0% to 200% of the target amount. The number of granted shares included in the table below is based on a maximum 200% achievement of each financial metric during each Performance Period (the “Maximum Performance Target”). If a financial metric is achieved at a rate below the Maximum Performance Target, or is not achieved, the corresponding portions of the PSUs that do not vest are forfeited.

The following summarizes our PSUs transaction activity for the six months ended October 31, 2023:

Schedule of PSU activity
	Shares		Weighted Average Grant Date Fair Value
		(in thousands)
Outstanding at May 1, 2023		522		$19.70
Granted		613		$13.92
Vested		–		$–
Forfeited		–		$–
Outstanding at October 31, 2023		1,135		$16.58

Employee Stock Purchase Plan

The Avid Bioservices, Inc. 2010 Employee Stock Purchase Plan (the “ESPP”) is a stockholder-approved plan under which employees can purchase shares of our common stock, based on a percentage of their compensation, subject to certain limits. The purchase price per share is equal to the lower of 85% of the fair market value of our common stock on the first trading day of the six-month offering period or on the last trading day of the six-month offering period. During the six months ended October 31, 2023, a total of 46,224 shares of our common stock were purchased under the ESPP at a purchase price of $11.46 per share. As of October 31, 2023, we had 917,092 shares of our common stock reserved for issuance under the ESPP.

Stock-Based Compensation

Stock-based compensation expense included in our unaudited condensed consolidated statements of income (loss) and comprehensive income (loss) for the three and six months ended October 31, 2023 and 2022 was comprised of the following (in thousands):


	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Cost of revenues	$	1,107	$	1,045	$	2,061	$	1,732
Selling, general and administrative		1,359		1,741		2,748		2,951
Total stock-based compensation	$	2,466	$	2,786	$	4,809	$	4,683

As of October 31, 2023, the total estimated unrecognized compensation cost related to non-vested stock options and RSUs was $0.7 million and $20.3 million, respectively. These costs are expected to be recognized over weighted average vesting periods of 0.73 and 2.87 years, respectively. As of October 31, 2023, there was $9.7 million of total estimated unrecognized compensation cost related to non-vested PSUs associated with the Performance Periods ending April 30, 2024, 2025 and 2026. This cost is expected to be recognized over the weighted average vesting period of 1.22 years, however, we will assess the likelihood of achieving the predetermined financial metrics associated with each Performance Period on a quarterly basis and the expense recognized, if any, will be adjusted accordingly.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ (11,602)	$ 408
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	5,433	3,409
Stock-based compensation	4,809	4,683
Amortization of debt issuance costs	639	520
Deferred income taxes	(2,978)	(1,565)
Loss on disposal of property and equipment	46	70
Changes in operating assets and liabilities:
Accounts receivable, net	4,919	(33)
Contract assets	(1,238)	(1,159)
Inventory	5,325	(12,999)
Prepaid expenses and other assets	(7,909)	(127)
Accounts payable	4,344	5,346
Accrued compensation and benefits	(4,536)	(2,411)
Contract liabilities	8,808	(5,352)
Other accrued expenses and liabilities	(239)	439
Net cash provided by (used in) operating activities	5,821	(8,771)
Cash flows from investing activities:
Purchase of property and equipment	(21,437)	(41,432)
Net cash used in investing activities	(21,437)	(41,432)
Cash flows from financing activities:
Proceeds from issuance of common stock under equity compensation plans	998	1,578
Proceeds from finance lease	7,412	0
Principal payments on finance lease	(262)	(249)
Net cash provided by financing activities	8,148	1,329
Net decrease in cash, cash equivalents and restricted cash	(7,468)	(48,874)
Cash, cash equivalents and restricted cash, beginning of period	38,892	126,516
Cash, cash equivalents and restricted cash, end of period	31,424	77,642
Supplemental disclosures of cash flow information:
Cash paid for interest	882	438
Cash paid for income taxes	14	220
Supplemental disclosures of non-cash investing activities:
Unpaid purchases of property and equipment	$ 7,972	$ 8,478

Summary of Significant Accounting Policies (Details - Useful life)	6 Months Ended
	Oct. 31, 2023
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	Shorter of estimated useful life or lease term
Other Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 – 15 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 – 5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 – 10 years

Summary of Significant Accounting Policies

6 Months Ended

Oct. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

Information regarding our significant accounting policies is contained in Note 2, “Summary of Significant Accounting Policies,” of the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended April 30, 2023.

Revenue Recognition

Revenue recognized from services provided under our customer contracts is disaggregated into manufacturing and process development revenue streams.

Manufacturing revenue

Manufacturing revenue generally represents revenue from the manufacturing of customer products recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a manufacturing contract, a quantity of manufacturing runs are ordered at a specified scale with prescribed dates, where the product is manufactured according to the customer’s specifications and typically includes only one performance obligation. Each manufacturing run represents a distinct service that is sold separately and has stand-alone value to the customer. The products are manufactured exclusively for a specific customer and have no alternative use. The customer retains control of its product during the entire manufacturing process and can make changes to the process or specifications at its request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin.

Process development revenue

Process development revenue generally represents revenue from services associated with the custom development of a manufacturing process and analytical methods for a customer’s product. Process development revenue is recognized over time utilizing an input method that compares the cost of cumulative work-in-process to date to the most current estimates for the entire cost of the performance obligation. Under a process development contract, the customer owns the product details and process, which has no alternative use. These process development projects are customized to each customer to meet its specifications and typically includes only one performance obligation. Each process represents a distinct service that is sold separately and has stand-alone value to the customer. The customer also retains control of its product as the product is being created or enhanced by our services and can make changes to its process or specifications upon request. Under these agreements, we are entitled to consideration for progress to date that includes an element of profit margin.

The following table summarizes our revenue streams (in thousands):

Schedule of revenues
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Manufacturing revenues	$	20,128	$	27,614	$	53,548	$	59,095
Process development revenues		5,267		7,143		9,573		12,354
Total revenues	$	25,395	$	34,757	$	63,121	$	71,449

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets (unbilled receivables), and contract liabilities (customer deposits and deferred revenue). Contract assets are recorded when our right to consideration is conditioned on something other than the passage of time. Contract assets are reclassified to accounts receivable on the consolidated balance sheet when our rights become unconditional. Contract liabilities represent customer deposits and deferred revenue billed and/or received in advance of our fulfillment of performance obligations. Contract liabilities convert to revenue as we perform our obligations under the contract.

During the three and six months ended October 31, 2023, we recognized revenue of $4.0 million and $20.8 million, respectively, for which the contract liability was recorded in a prior period.

During the three and six months ended October 31, 2022, we recognized revenue of $8.3 million and $26.9 million, respectively, for which the contract liability was recorded in a prior period.

The transaction price for services provided under our customer contracts reflects our best estimates of the amount of consideration to which we are entitled in exchange for providing goods and services to our customers. For contracts with multiple performance obligations, we allocate transaction price to each performance obligation identified in a contract on a relative standalone selling price basis. For contracts in which we receive noncash consideration such as in the form of a customer’s equity securities, we utilize the quoted market price for such noncash consideration to determine the transaction price. We generally determine relative standalone selling prices based on the price observed in the customer contract for each distinct performance obligation. If observable standalone selling prices are not available, we may estimate the applicable standalone selling price based on the pricing of other comparable services or on a price that we believe the market is willing to pay for the applicable service.

In determining the transaction price, we also considered the different sources of variable consideration including, but not limited to, discounts, credits, refunds, price concessions or other similar items. We have included in the transaction price some or all of an amount of variable consideration, utilizing the most likely method, only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The actual amount of consideration ultimately received may differ.

In addition, our customer contracts generally include provisions entitling us to a cancellation or postponement fee when a customer cancels or postpones its commitments prior to our initiation of services, therefore not utilizing their reserved capacity. The determination of such cancellation and postponement fees are based on the terms stated in the related customer contract but are generally considered substantive for accounting purposes and create an enforceable right and obligation due to us when the cancellation or postponement occurs. Accordingly, we recognize such fees, subject to variable consideration, as revenue upon the cancellation or postponement date utilizing the most likely method.

Management may be required to exercise judgement in estimating revenue to be recognized. Judgement is required in identifying performance obligations, estimating the transaction price, estimating the stand-alone selling prices of identified performance obligations, estimating variable consideration, and estimating the progress towards the satisfaction of performance obligations. If actual results in the future vary from our estimates, the estimates will be adjusted, which will affect revenues in the period that such variances become known.

During the three and six months ended October 31, 2023, changes in estimates for variable consideration resulted in a decrease in revenues of $1.8 million and $3.2 million, respectively. The changes in estimates for variable consideration can be attributed to an insolvent customer combined with consideration under a contract where uncertainties have been resolved. There were no material adjustments in estimates for variable consideration for the three and six months ended October 31, 2022.

We apply the practical expedient available under ASC 606 that permits us not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. As of October 31, 2023, we do not have any unsatisfied performance obligations for contracts greater than one year.

Costs incurred to obtain a contract are not material. These costs are generally employee sales commissions, which are expensed as incurred and included in selling, general and administrative expense in the unaudited condensed consolidated statements of income (loss) and comprehensive income (loss).

Restricted Cash

Under the terms of an operating lease related to one of our non-manufacturing facilities that was primarily utilized for office space (Note 4), we were required to maintain a letter of credit as collateral during the term of the lease. As of October 31, 2023, no restricted cash remained pledged as collateral for the letter of credit as the associated operating lease has expired. As of April 30, 2023, restricted cash of $0.4 million was pledged as collateral under the letter of credit.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands):

Schedule of cash
	October 31, 2023		April 30, 2023		October 31, 2022		April 30, 2022
Cash and cash equivalents	$	31,424	$	38,542	$	77,292	$	126,166
Restricted cash		–		350		350		350
Total cash, cash equivalents and restricted cash	$	31,424	$	38,892	$	77,642	$	126,516

Accounts Receivable, Net

Accounts receivable is primarily comprised of amounts owed to us for services provided under our customer contracts and are recorded at the invoiced amount net of an allowance for doubtful accounts, if necessary. We apply judgement in assessing the ultimate realization of our receivables, that includes an assessment of expected credit losses, and we estimate our allowance for doubtful accounts based on various factors, including our historical collection experience, aging of our customer receivable balances, current and future economic market conditions, and the financial condition of our customers.

Based on our analysis of our accounts receivable balance as of October 31, 2023 and April 30, 2023, we determined an allowance for doubtful accounts of $1.6 million and $0.5 million, respectively, was deemed necessary.

Inventory

Inventory consists of raw materials inventory and is valued at the lower of cost, determined by the first-in, first-out method, or net realizable value. We periodically review raw materials inventory for potential impairment and adjust inventory to its net realizable value based on the estimate of future use and reduce the carrying value of inventory as deemed necessary.

Property and Equipment

Property and equipment is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related asset, which are generally as follows:


Description		Estimated Useful Life
Leasehold improvements		Shorter of estimated useful life or lease term
Laboratory and manufacturing equipment		5 – 15 years
Computer equipment and software		3 – 5 years
Furniture, fixtures and office equipment		5 – 10 years

Costs for property and equipment not yet placed into service have been capitalized as construction-in-progress. These costs are primarily related to equipment and leasehold improvements associated with our manufacturing facilities and will be depreciated in accordance with the above guidelines once placed into service. Interest costs incurred during construction of major capital projects are capitalized as construction-in-progress until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. Interest capitalized as construction-in-progress was de minimis for the three months ended October 31, 2023, and $0.1 million for the six months ended October 31, 2023. Interest capitalized as construction-in-progress was de minimis for the three months ended October 31, 2022, and $0.3 million for the six months ended October 31, 2022. All of our property and equipment are located in the United States. Property and equipment consist of the following (in thousands):

Schedule of property and equipment
	October 31, 2023			April 30, 2023
Leasehold improvements	$	101,310		$	97,514
Laboratory and manufacturing equipment		43,336			35,501
Computer equipment and software		5,170			5,028
Furniture, fixtures and office equipment		1,910			1,681
Construction-in-progress		71,124			68,013
Total property and equipment, gross		222,850			207,737
Less: accumulated depreciation and amortization		(35,676	)		(30,368	)
Total property and equipment, net	$	187,174		$	177,369

Depreciation and amortization expense for the three and six months ended October 31, 2023 was $2.8 million and $5.4 million, respectively.

Depreciation and amortization expense for the three and six months ended October 31, 2022 was $1.8 million and $3.4 million, respectively.

Leases

We determine if an arrangement is or contains a lease at inception. Our operating leases with a term greater than one year are included in operating lease right-of-use (“ROU”) assets, operating lease liabilities and operating lease liabilities, less current portion in our consolidated balance sheets. ROU assets represent our right to use an underlying asset during the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date, based on the present value of lease payments over the lease term. In determining the net present value of lease payments, we use our incremental borrowing rate which represents an estimated rate of interest that we would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date.

Our operating leases may include options to extend the lease which are included in the lease term when it is reasonably certain that we will exercise a renewal option. Operating lease expense is recognized on a straight-line basis over the expected lease term.

Our finance leases with a term greater than one year are included as assets within property and equipment, net and a lease liability equal to the present value of the minimum lease payments is included in other current liabilities and finance lease liabilities, less current portion in our consolidated balance sheets. The present value of the finance lease payments is calculated using the implicit interest rate in the lease. Finance lease ROU assets are amortized on a straight-line basis over the expected useful life of the asset and the carrying amount of the lease liability is adjusted to reflect interest, which is recorded as interest expense.

Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets and lease expense for these short-term leases is recognized on a straight-line basis over the lease term. We have also elected the practical expedient to not separate lease components from non-lease components.

Impairment

Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. If such events or changes in circumstances arise, we compare the carrying amount of the long-lived assets to the estimated future undiscounted cash flows expected to be generated by the long-lived assets. If the long-lived assets are determined to be impaired, any excess of the carrying value of the long-lived assets over its estimated fair value is recognized as an impairment loss. For the six months ended October 31, 2023 and 2022, there were no indicators of impairment of the value of our long-lived assets and no cumulative impairment losses were recognized as of October 31, 2023.

Stock-Based Compensation

We account for stock options, restricted stock units, performance stock units and other stock-based awards granted under our equity compensation plans in accordance with the authoritative guidance of ASC 718, Compensation – Stock Compensation. The estimated fair value of stock options granted to employees in exchange for services is measured at the grant date, using a fair value-based method, such as a Black-Scholes option valuation model, and is recognized as an expense on a straight-line basis over the requisite service periods. The fair value of restricted stock units and performance stock units is measured at the grant date based on the closing market price of our common stock on the date of grant. For restricted stock units, the fair value is recognized as an expense on a straight-line basis over the requisite service periods. For performance stock units, which are subject to performance conditions, the fair value is recognized as expense on a straight-line basis over the requisite service periods when the achievement of such performance condition is determined to be probable. If a performance condition is not determined to be probable or is not met, no stock-based compensation expense is recognized, and any previously recognized expense is reversed. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.

Debt Issuance Costs

Debt issuance costs related to convertible senior notes are recorded as a deduction that is netted against the principal value of the debt and are amortized to interest expense using the effective interest method over the contractual term of the debt (Note 3).

Debt issuance costs related to the revolving credit facility are included in prepaid expenses and other current assets in the consolidated balance sheet and are amortized to interest expense over the contractual term of the revolving credit facility (Note 3).

Comprehensive Income (Loss)

Comprehensive income (loss) is the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is equal to our net income (loss) for all periods presented.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:

	·	Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.
	·	Level 2 – Observable inputs other than quoted prices included in Level 1, such as assets or liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
	·	Level 3 – Unobservable inputs that are supported by little or no market activity and significant to the overall fair value measurement of the assets or liabilities; therefore, requiring the company to develop its own valuation techniques and assumptions.

As of October 31, 2023 and April 30, 2023, our Level 1 financial assets consisted of our cash equivalents invested in money market funds of $21.6 million and $28.7 million, respectively, and our other current assets related to investments in equity securities of $7.5 million and $0, respectively. Our Level 1 financial assets are carried at a fair value based on quoted market prices for identical securities (Level 1 input). We did not have any Level 2 or Level 3 financial assets as of October 31, 2023 and April 30, 2023.

We consider the fair value of our senior convertible notes to be a Level 2 financial liability due to limited trading activity of the senior convertible notes (Note 3). We did not have any other Level 2 or Level 3 financial liabilities as of October 31, 2023 and April 30, 2023.

Recently Adopted Accounting Standard

In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments (“ASU 2016-13”). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments. We adopted ASU 2016-13 on May 1, 2023, and the adoption of this standard did not have a material impact on our unaudited condensed consolidated financial statements.

Equity Compensation Plans (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member] shares in Thousands	6 Months Ended
	Oct. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding beginning balance \| shares	1,006
Weighted average grant date fair value, Outstanding beginning balance \| $ / shares	$ 16.83
RSUs shares, Granted \| shares	673
RSUs weighted average grant date fair value, Granted \| $ / shares	$ 14.00
RSUs shares, Vested \| shares	(274)
RSUs weighted average grant date fair value, Vested \| $ / shares	$ 13.73
RSUs shares, Forfeited \| shares	(40)
RSUs weighted average grant date fair value, Forfeited \| $ / shares	$ 16.98
Outstanding ending balance \| shares	1,365
Weighted average grant date fair value, Outstanding ending balance \| $ / shares	$ 16.05

Income Taxes (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022	Apr. 30, 2023
Income Tax Disclosure [Abstract]
Income tax benefit	$ 2,400	$ 2,100	$ 3,000	$ 1,400
Effective tax rate	20.00%	64.30%	20.40%	141.80%
Uncertain tax positions	$ 0		$ 0		$ 0
Accrued interest or penalties	$ 0		$ 0		$ 0

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Oct. 31, 2023

Accounting Policies [Abstract]

Revenue Recognition

Revenue Recognition

Revenue recognized from services provided under our customer contracts is disaggregated into manufacturing and process development revenue streams.

Manufacturing revenue

Process development revenue

The following table summarizes our revenue streams (in thousands):

Schedule of revenues
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Manufacturing revenues	$	20,128	$	27,614	$	53,548	$	59,095
Process development revenues		5,267		7,143		9,573		12,354
Total revenues	$	25,395	$	34,757	$	63,121	$	71,449

During the three and six months ended October 31, 2023, we recognized revenue of $4.0 million and $20.8 million, respectively, for which the contract liability was recorded in a prior period.

During the three and six months ended October 31, 2022, we recognized revenue of $8.3 million and $26.9 million, respectively, for which the contract liability was recorded in a prior period.

Restricted Cash

Restricted Cash

Schedule of cash
	October 31, 2023		April 30, 2023		October 31, 2022		April 30, 2022
Cash and cash equivalents	$	31,424	$	38,542	$	77,292	$	126,166
Restricted cash		–		350		350		350
Total cash, cash equivalents and restricted cash	$	31,424	$	38,892	$	77,642	$	126,516

Accounts Receivable, Net

Accounts Receivable, Net

Inventory

Inventory

Property and Equipment

Property and Equipment


Description		Estimated Useful Life
Leasehold improvements		Shorter of estimated useful life or lease term
Laboratory and manufacturing equipment		5 – 15 years
Computer equipment and software		3 – 5 years
Furniture, fixtures and office equipment		5 – 10 years

Schedule of property and equipment
	October 31, 2023			April 30, 2023
Leasehold improvements	$	101,310		$	97,514
Laboratory and manufacturing equipment		43,336			35,501
Computer equipment and software		5,170			5,028
Furniture, fixtures and office equipment		1,910			1,681
Construction-in-progress		71,124			68,013
Total property and equipment, gross		222,850			207,737
Less: accumulated depreciation and amortization		(35,676	)		(30,368	)
Total property and equipment, net	$	187,174		$	177,369

Depreciation and amortization expense for the three and six months ended October 31, 2023 was $2.8 million and $5.4 million, respectively.

Depreciation and amortization expense for the three and six months ended October 31, 2022 was $1.8 million and $3.4 million, respectively.

Leases

Leases

Impairment

Impairment

Stock-Based Compensation

Stock-Based Compensation

Debt Issuance Costs

Debt Issuance Costs

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Fair Value Measurements

Fair Value Measurements

	·	Level 1 – Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.
	·	Level 2 – Observable inputs other than quoted prices included in Level 1, such as assets or liabilities whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.
	·	Level 3 – Unobservable inputs that are supported by little or no market activity and significant to the overall fair value measurement of the assets or liabilities; therefore, requiring the company to develop its own valuation techniques and assumptions.

Recently Adopted Accounting Standard

Recently Adopted Accounting Standard

Debt (Details - Interest expense) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Debt (Details - Interest expense) - USD ($) $ in Thousands	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Short-Term Debt [Line Items]
Amortization of issuance costs			$ 639	$ 520
Total interest expense associated with Convertible Notes	$ 805	$ 703	1,580	1,221
Convertible Notes [Member]
Short-Term Debt [Line Items]
Contractual interest expense	431	411	839	635
Amortization of issuance costs	266	260	531	520
Total interest expense associated with Convertible Notes	$ 697	$ 671	$ 1,370	$ 1,155

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Apr. 30, 2022	$ 62	$ 605,841	$ (431,377)	$ 174,526
Beginning balance, shares at Apr. 30, 2022	61,807
Common stock issued under equity compensation plans		1,578		1,578
Common stock issued under equity compensation plans, shares	501
Stock-based compensation expense		4,683		4,683
Net income			408	408
Ending balance, value at Oct. 31, 2022	$ 62	612,102	(430,969)	181,195
Ending balance, shares at Oct. 31, 2022	62,308
Beginning balance, value at Jul. 31, 2022	$ 62	608,750	(429,813)	178,999
Beginning balance, shares at Jul. 31, 2022	62,165
Common stock issued under equity compensation plans		566		566
Common stock issued under equity compensation plans, shares	143
Stock-based compensation expense		2,786		2,786
Net income			(1,156)	(1,156)
Ending balance, value at Oct. 31, 2022	$ 62	612,102	(430,969)	181,195
Ending balance, shares at Oct. 31, 2022	62,308
Beginning balance, value at Apr. 30, 2023	$ 63	620,224	(430,817)	189,470
Beginning balance, shares at Apr. 30, 2023	62,692
Common stock issued under equity compensation plans		998		998
Common stock issued under equity compensation plans, shares	542
Stock-based compensation expense		4,809		4,809
Net income			(11,602)	(11,602)
Ending balance, value at Oct. 31, 2023	$ 63	626,031	(442,419)	183,675
Ending balance, shares at Oct. 31, 2023	63,234
Beginning balance, value at Jul. 31, 2023	$ 63	623,445	(432,910)	190,598
Beginning balance, shares at Jul. 31, 2023	63,111
Common stock issued under equity compensation plans		120		120
Common stock issued under equity compensation plans, shares	123
Stock-based compensation expense		2,466		2,466
Net income			(9,509)	(9,509)
Ending balance, value at Oct. 31, 2023	$ 63	$ 626,031	$ (442,419)	$ 183,675
Ending balance, shares at Oct. 31, 2023	63,234

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Oct. 31, 2023	Apr. 30, 2023
Current assets:
Cash and cash equivalents	$ 31,424	$ 38,542
Accounts receivable, net	13,379	18,298
Contract assets	10,847	9,609
Inventory	38,583	43,908
Prepaid expenses and other current assets	9,972	2,094
Total current assets	104,205	112,451
Property and equipment, net	187,174	177,369
Operating lease right-of-use assets	41,973	42,772
Deferred tax assets	116,617	113,639
Other assets	4,673	4,473
Restricted cash	0	350
Total assets	454,642	451,054
Current liabilities:
Accounts payable	22,784	24,593
Accrued compensation and benefits	4,244	8,780
Contract liabilities	46,437	37,352
Current portion of operating lease liabilities	1,263	1,358
Other current liabilities	2,209	1,626
Total current liabilities	76,937	73,709
Convertible senior notes, net	141,154	140,623
Operating lease liabilities, less current portion	45,036	45,690
Finance lease liabilities, less current portion	7,840	1,562
Total liabilities	270,967	261,584
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates	0	0
Common stock, $0.001 par value; 150,000 shares authorized; 63,234 and 62,692 shares issued and outstanding at respective dates	63	63
Additional paid-in capital	626,031	620,224
Accumulated deficit	(442,419)	(430,817)
Total stockholders’ equity	183,675	189,470
Total liabilities and stockholders’ equity	$ 454,642	$ 451,054

Leases (Details - Maturities of Operating Lease Liabilities) $ in Thousands	Oct. 31, 2023 USD ($)
2024 (remaining period)	$ 2,972
2025	6,023
2026	6,130
2027	5,953
2028	5,370
Thereafter	59,754
Total lease payments	86,202
Less: imputed interest	(30,660)
Total lease liabilities	55,542
Operating Lease [Member]
2024 (remaining period)	1,990
2025	4,060
2026	4,167
2027	4,199
2028	4,036
Thereafter	56,418
Total lease payments	74,870
Less: imputed interest	(28,571)
Total lease liabilities	46,299
Finance Lease [Member]
2024 (remaining period)	982
2025	1,963
2026	1,963
2027	1,754
2028	1,334
Thereafter	3,336
Total lease payments	11,332
Less: imputed interest	(2,089)
Total lease liabilities	$ 9,243

Debt

6 Months Ended

Oct. 31, 2023

Debt Disclosure [Abstract]

Debt

Note 3 – Debt

Convertible Senior Notes Due 2026

In March 2021, we issued $143.8 million in aggregate principal amount of 1.25% exchangeable senior notes due 2026 (“Convertible Notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The net proceeds we received from the issuance of Convertible Notes was $138.5 million, after deducting initial purchaser discounts and other debt issuance related expenses of $5.3 million.

The Convertible Notes are senior unsecured obligations and accrue interest at a rate of 1.25% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. The Convertible Notes mature on March 15, 2026, unless earlier redeemed or repurchased by us or converted at the option of the holders. The Convertible Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election in the manner and subject to the terms and conditions provided in the indenture (the “Indenture”) governing the Convertible Notes.

The initial conversion rate for the Convertible Notes is approximately 47.1403 shares of our common stock per $1,000 principal amount, which represents an initial conversion price of approximately $21.21 per share of our common stock. The conversion rate is subject to adjustments upon the occurrence of certain events in accordance with the terms of the Indenture. In addition, following certain corporate events that occur prior to the maturity date, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert their Convertible Notes in connection with such a fundamental change, as defined in the Indenture.

Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding September 15, 2025, only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending July 31, 2021, if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the exchange rate on each such trading day; (3) if we call any or all of the Convertible Notes for redemption, at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date; and (4) upon the occurrence of specified corporate events as described in the Indenture.

On or after September 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders at their option may convert their Convertible Notes at any time, regardless of the foregoing circumstances.

We may not redeem the Convertible Notes prior to March 20, 2024. On or after March 20, 2024, the Convertible Notes are redeemable for cash, whole or in part, at our option, if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their Convertible Notes at a fundamental change repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding the redemption date.

The Indenture contains customary terms and covenants, including that upon certain events of default occurring and continuing, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare the entire principal of all the Convertible Notes plus accrued and unpaid interest to be immediately due and payable.

As of October 31, 2023, the conditions allowing holders of the Convertible Notes to convert had not been met and, therefore, the Convertible Notes are classified as a long-term liability on the unaudited condensed consolidated balance sheets at October 31, 2023 and April 30, 2023.

The net carrying amount of the Convertible Notes is as follows (in thousands):


	October 31, 2023			April 30, 2023
Principal	$	143,750		$	143,750
Unamortized issuance costs		(2,596	)		(3,127	)
Net carrying amount	$	141,154		$	140,623

As of October 31, 2023, the estimated fair value of the Convertible Notes was approximately $116.9 million. The fair value was determined based on the last actively traded price per $100 of the Convertible Notes for the period ended October 31, 2023 (Level 2).

The following table summarizes the interest expense recognized related to the Convertible Notes for the three and six months ended October 31, 2023 and 2022 (in thousands):

Schedule of interest expense
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Contractual interest expense	$	431	$	411	$	839	$	635
Amortization of issuance costs		266		260		531		520
Total interest expense associated with Convertible Notes	$	697	$	671	$	1,370	$	1,155

Capped Call Transactions

In connection with the issuance of the Convertible Notes, we entered into privately negotiated capped call transactions (the “Capped Calls”) with certain financial institution counterparties (the “Option Counterparties”). We used $12.8 million of the net proceeds from the issuance of the Convertible Notes to pay the cost of the Capped Calls. The Capped Calls cover, subject to customary anti-dilution adjustments, the aggregate number of shares of our common stock that initially underlie the Convertible Notes, and are generally expected to reduce the potential dilution of our common stock upon any conversion of the Convertible Notes, as the case may be, with such reduction and/or offset subject to a cap, based on the cap price of the Capped Calls. The cap share price of the Capped Calls is approximately $28.02 per share, which represents a premium of 75% over the last reported sale price of our common stock on March 9, 2021 and is subject to certain adjustments under the terms of the Capped Calls. However, there would nevertheless be dilution upon conversion of the Convertible Notes to the extent that such market price exceeds the capped share price as measured under the terms of the Capped Calls.

We evaluated the Capped Calls under ASC 815-10 and determined that they should be accounted for as a separate transaction from the Convertible Notes and that the Capped Calls met the criteria for equity classification. Therefore, the cost of $12.8 million to purchase the Capped Calls was recorded as a reduction to additional paid-in capital. The Capped Calls will not be subsequently remeasured as long as the conditions for equity classification continue to be met. As of October 31, 2023 and April 30, 2023, there were no conversions of our Convertible Notes, and therefore, there was no activity with respect to the Capped Calls. We believe the conditions for equity classification continue to be met as of October 31, 2023 and April 30, 2023.

Revolving Credit Facility

On March 14, 2023, we entered into a credit agreement with Bank of America, N.A., as administrative agent and letter of credit issuer (the “Credit Agreement”). The Credit Agreement provides for a revolving credit facility (the “Revolving Credit Facility”) in an amount equal to the lesser of (i) $50 million and (ii) a borrowing base calculated as the sum of (a) 80% of the value of certain of our eligible accounts receivable, plus (b) up to 100% of the value of eligible cash collateral. The Credit Agreement is secured by substantially all our assets.

On October 27, 2023, we entered into Amendment No. 1 to the Credit Agreement which, among other things, (i) extends the maturity date of the Revolving Credit Facility to October 25, 2024, (ii) amends the applicable interest rate applied to loans under the Revolving Credit Facility as described below, and (iii) increases the aggregate amount of indebtedness we can incur at any one time for fixed or capital assets. Other than the foregoing, the material terms of the Credit Facility remain unchanged.

As of October 31, 2023, there were no outstanding loans under the Revolving Credit Facility.

Loans under the Revolving Credit Facility will bear interest at either a term Secured Overnight Financing Rate (“SOFR”) rate for a specified interest period plus a SOFR adjustment (equal to 0.10%) plus a margin of 1.60% or base rate plus a margin of 0.60% at our option. Interest on any outstanding loans is due and payable monthly and the principal balance is due at maturity. In addition, we pay a quarterly unused revolving line facility fee of 0.25% per annum on the average unused facility.

The Credit Agreement includes certain customary affirmative and negative covenants, including limitations on mergers, consolidations and sales of assets, limitations on liens, limitations on certain restricted payments and investments, limitations on transactions with affiliates and limitations on incurring additional indebtedness. In addition, the Credit Agreement, as amended, requires maintenance of a minimum consolidated EBITDA, as defined in the Credit Agreement, of $15 million for the most recently completed four fiscal quarters as measured at the end of each fiscal quarter. As of October 31, 2023, we were in compliance with the Credit Agreement’s financial covenant.

The Credit Agreement, as amended, also provides for certain customary events of defaults, including, among others, failure to make payments, breach of representations and warranties, and default of covenants.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Deferred Compensation Plan

6 Months Ended

Oct. 31, 2023

Retirement Benefits [Abstract]

Deferred Compensation Plan

Note 6 - Deferred Compensation Plan

In July 2023, our Board of Directors approved and adopted the Avid Bioservices, Inc. Deferred Compensation Plan (the “DC Plan”). The DC Plan allows non-employee directors and certain highly compensated employees to defer a portion of their base compensation, cash bonuses, and certain restricted stock unit and performance stock unit awards. As of October 31, 2023, contributions to the DC Plan were not material and are included in accrued compensation and benefits on the unaudited condensed consolidated balance sheet at October 31, 2023.

Leases (Details - Components of lease) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Leases
Operating lease cost	$ 1,150	$ 1,090	$ 2,290	$ 2,173
Variable lease cost	424	408	775	797
Short-term lease cost	31	197	67	327
Finance lease costs:
Amortization of right-of-use assets	54	54	108	108
Interest on lease liabilities	25	33	52	66
Total lease cost	$ 1,684	$ 1,782	$ 3,292	$ 3,471

Net Income (Loss) Per Common Share (Details - Antidilutive shares) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	9,053	8,613	8,979	7,467
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	877	1,404	962	51
R S Us P S Us And E S P P [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	1,400	433	1,241	640
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive effect of shares on diluted shares outstanding	6,776	6,776	6,776	6,776

Debt (Tables)

6 Months Ended

Oct. 31, 2023

Debt Disclosure [Abstract]

Schedule of net carrying amount of the debt component


	October 31, 2023			April 30, 2023
Principal	$	143,750		$	143,750
Unamortized issuance costs		(2,596	)		(3,127	)
Net carrying amount	$	141,154		$	140,623

Schedule of interest expense

Schedule of interest expense
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Contractual interest expense	$	431	$	411	$	839	$	635
Amortization of issuance costs		266		260		531		520
Total interest expense associated with Convertible Notes	$	697	$	671	$	1,370	$	1,155

Leases (Details - Operating leases assets and liabilities) - USD ($) $ in Thousands	Oct. 31, 2023	Apr. 30, 2023
Leases
Operating lease right-of-use assets	$ 41,973	$ 42,772
Finance Property and equipment, net	9,803	2,529
Total leased assets	51,776	45,301
Current portion of operating lease liabilities	1,263	1,358
Finance other current liabilities	1,403	531
Operating lease liabilities, less current portion	45,036	45,690
Finance lease liabilities, less current portion	7,840	1,562
Total lease liabilities	$ 55,542	$ 49,141

Debt (Details - Debt component) - Convertible Debt Carrying Amount [Member] - USD ($) $ in Thousands	Oct. 31, 2023	Apr. 30, 2023
Debt Instrument [Line Items]
Principal	$ 143,750	$ 143,750
Unamortized issuance costs	(2,596)	(3,127)
Net carrying amount	$ 141,154	$ 140,623

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Leases (Details - Supplemental cash flow information) - USD ($) $ in Thousands	6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 2,149	$ 2,063
Operating cash flows from finance leases	52	65
Financing cash flows from finance leases	$ 262	$ 249

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares shares in Thousands	Oct. 31, 2023	Apr. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000	150,000
Common stock, shares issued	63,234	62,692
Common stock, shares outstanding	63,234	62,692

Summary of Significant Accounting Policies (Details - Property and Equipment) - USD ($) $ in Thousands	Oct. 31, 2023	Apr. 30, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 222,850	$ 207,737
Less: Accumulated depreciation and amortization	(35,676)	(30,368)
Total property and equipment, net	187,174	177,369
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	101,310	97,514
Manufactured Product, Other [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	43,336	35,501
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	5,170	5,028
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	1,910	1,681
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, gross	$ 71,124	$ 68,013

Equity Compensation Plans (Details - Option activity) - Equity Option [Member] shares in Thousands	6 Months Ended
	Oct. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options, Outstanding beginning balance \| shares	2,079
Grant date weighted average exercise price, Outstanding beginning balance \| $ / shares	$ 6.76
Stock options, Granted \| shares	0
Grant date weighted average exercise price, Granted \| $ / shares	$ 0
Stock options, Exercised \| shares	(62)
Grant date weighted average exercise price, Exercised \| $ / shares	$ 7.65
Stock options, Cancelled or expired \| shares	(16)
Grant date weighted average exercise price, Canceled or expired \| $ / shares	$ 11.99
Stock options, Outstanding ending balance \| shares	2,001
Grant date weighted average exercise price, Outstanding ending balance \| $ / shares	$ 6.69

Net Income (Loss) Per Common Share (Tables)

6 Months Ended

Oct. 31, 2023

Net income (loss) per share:

Schedule of earnings per share, basic and diluted


	Three Months Ended October 31,						Six Months Ended October 31,
	2023			2022			2023			2022
Numerator
Net income (loss)	$	(9,509	)	$	(1,156	)	$	(11,602	)	$	408
Denominator
Weighted average basic common shares outstanding		63,149			62,204			62,994			62,054
Effect of dilutive securities:
Stock options		–			–			–			1,294
RSUs, PSUs and ESPP		–			–			–			226
Weighted average dilutive common shares outstanding		63,149			62,204			62,994			63,574
Net income (loss) per share:
Basic	$	(0.15	)	$	(0.02	)	$	(0.18	)	$	0.01
Diluted	$	(0.15	)	$	(0.02	)	$	(0.18	)	$	0.01

Schedule of antidilutive shares

Schedule of antidilutive shares
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Stock options		877		1,404		962		51
RSUs, PSUs and ESPP		1,400		433		1,241		640
Convertible Notes		6,776		6,776		6,776		6,776
Total		9,053		8,613		8,979		7,467

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022	Apr. 30, 2023
Accounting Policies [Abstract]
Revenue recognized	$ 4.0	$ 8.3	$ 20.8	$ 26.9
Change in revenue due to change in estimate	1.8		3.2
Restricted cash					$ 0.4
Allowance for doubtful accounts	1.6		1.6		0.5
Capitalized Interest Costs, Including Allowance for Funds Used During Construction			0.1	0.3
Depreciation and amortization expense	2.8	$ 1.8	5.4	$ 3.4
Cash equivalents	21.6		21.6		28.7
Investment in equity securities	$ 7.5		$ 7.5		$ 0.0

Commitments and Contingencies

6 Months Ended

Oct. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9 – Commitments and Contingencies

In the ordinary course of business, we are at times subject to various legal proceedings and disputes. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions, if any, are reviewed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated financial condition or results of operations.

Equity Compensation Plans (Tables)

6 Months Ended

Oct. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of stock option activity

Schedule of stock option activity
	Stock Options		Grant Date Weighted Average Exercise Price
		(in thousands)
Outstanding at May 1, 2023		2,079		$6.76
Granted		–		$–
Exercised		(62)		$7.65
Canceled or expired		(16)		$11.99
Outstanding at October 31, 2023		2,001		$6.69

Schedule of RSU activity

Schedule of RSU activity
	Shares		Weighted Average Grant Date Fair Value
		(in thousands)
Outstanding at May 1, 2023		1,006		$16.83
Granted		673		$14.00
Vested		(274)		$13.73
Forfeited		(40)		$16.98
Outstanding at October 31, 2023		1,365		$16.05

Schedule of PSU activity

Schedule of PSU activity
	Shares		Weighted Average Grant Date Fair Value
		(in thousands)
Outstanding at May 1, 2023		522		$19.70
Granted		613		$13.92
Vested		–		$–
Forfeited		–		$–
Outstanding at October 31, 2023		1,135		$16.58

Schedule of share-based compensation expense


	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Cost of revenues	$	1,107	$	1,045	$	2,061	$	1,732
Selling, general and administrative		1,359		1,741		2,748		2,951
Total stock-based compensation	$	2,466	$	2,786	$	4,809	$	4,683

Leases

6 Months Ended

Oct. 31, 2023

Leases

Leases

Note 4 – Leases

We lease certain office, manufacturing, laboratory and warehouse space located in Orange County, California under operating lease agreements. Our leased facilities have original lease terms ranging from 7 to 12 years, contain multi-year renewal options, and scheduled rent increases of 3% on either an annual or biennial basis. Multi-year renewal options were included in determining the right-of-use asset and lease liability for each of our leases as we considered it reasonably certain that we would exercise such renewal options. In addition, certain of our leases provide for periods of free rent, lessor improvements and tenant improvement allowances, of which certain of these improvements have been classified as leasehold improvements and/or are being amortized over the shorter of the estimated useful life of the improvements or the remaining term of the lease.

Certain of our operating facility leases require us to pay property taxes, insurance and common area maintenance. While these payments are not included as part of our lease liabilities, they are recognized as variable lease cost in the period they are incurred.

We also lease certain manufacturing equipment under finance lease agreements that have terms ranging from 5 to 7 years.

The components of our lease costs for the three and six months ended October 31, 2023 and 2022 were as follows (in thousands):

Schedule of lease costs
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Operating lease cost	$	1,150	$	1,090	$	2,290	$	2,173
Variable lease cost		424		408		775		797
Short-term lease cost		31		197		67		327
Finance lease costs:
Amortization of right-of-use assets		54		54		108		108
Interest on lease liabilities		25		33		52		66
Total lease cost	$	1,684	$	1,782	$	3,292	$	3,471

Supplemental consolidated balance sheet and other information related to our leases as of October 31, 2023 and April 30, 2023 were as follows (in thousands, expect weighted average data):


Leases	Classification	October 31, 2023		April 30, 2023
Assets
Operating	Operating lease right-of-use assets	$	41,973	$	42,772
Finance	Property and equipment, net		9,803		2,529
Total leased assets		$	51,776	$	45,301

Liabilities
Current:
Operating	Current portion of operating lease liabilities	$	1,263	$	1,358
Finance	Other current liabilities		1,403		531
Non-current:
Operating	Operating lease liabilities, less current portion		45,036		45,690
Finance	Finance lease liabilities, less current portion		7,840		1,562
Total lease liabilities		$	55,542	$	49,141


Weighted average remaining lease term (years):
Operating leases	16.2	16.6
Finance leases	6.2	3.7
Weighted average discount rate:
Operating leases	6.0%	6.0%
Finance leases	6.4%	5.3%

Supplemental cash flow information related to our leases for the six months ended October 31, 2023 and 2022 were as follows (in thousands):


	Six Months Ended October 31,
	2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,149	$	2,063
Operating cash flows from finance leases		52		65
Financing cash flows from finance leases		262		249

As of October 31, 2023, the maturities of our lease liabilities, which includes those derived from lease renewal options that we considered it reasonably certain that we would exercise, were as follows (in thousands):


Fiscal Year Ending April 30,	Operating Leases			Finance Leases			Total
2024 (remaining period)	$	1,990		$	982		$	2,972
2025		4,060			1,963			6,023
2026		4,167			1,963			6,130
2027		4,199			1,754			5,953
2028		4,036			1,334			5,370
Thereafter		56,418			3,336			59,754
Total lease payments	$	74,870		$	11,332		$	86,202
Less: imputed interest		(28,571	)		(2,089	)		(30,660	)
Total lease liabilities	$	46,299		$	9,243		$	55,542

Equity Compensation Plans (Details - Share based compensation) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	$ 2,466	$ 2,786	$ 4,809	$ 4,683
Cost of Sales [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	1,107	1,045	2,061	1,732
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation	$ 1,359	$ 1,741	$ 2,748	$ 2,951

Cover - shares	6 Months Ended
Cover - shares	Oct. 31, 2023	Nov. 27, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--04-30
Entity File Number	001-32839
Entity Registrant Name	AVID BIOSERVICES, INC.
Entity Central Index Key	0000704562
Entity Tax Identification Number	95-3698422
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	14191 Myford Road
Entity Address, City or Town	Tustin
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92780
City Area Code	(714)
Local Phone Number	508-6100
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	CDMO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		63,239,238

Debt (Details Narrative) - USD ($) $ in Thousands		1 Months Ended	6 Months Ended
Debt (Details Narrative) - USD ($) $ in Thousands	Mar. 14, 2023	Mar. 31, 2021	Oct. 31, 2023
Debt Instrument [Line Items]
Net proceeds from convertible notes			$ 12,800
Revolving Credit Facility [Member] \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Revolving line facility fee	0.25%
Revolving Credit Facility [Member] \| Credit Agreement [Member]
Debt Instrument [Line Items]
Outstanding loans			0
Line of credit	$ 15,000
Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Aggregate principal amount		$ 143,800
Proceeds from convertible debt		138,500
Debt issuance costs		$ 5,300
Interest rate		1.25%
Maturity date		Mar. 15, 2026
Convertible Notes [Member]
Debt Instrument [Line Items]
Fair value of the convertible notes			$ 116,900

Equity Compensation Plans (Details Narrative) $ / shares in Units, $ in Millions	6 Months Ended
	Oct. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	7,682,971
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	917,092
Stock issued during period, ESPP	46,224
ESPP weighted average purchase price \| $ / shares	$ 11.46
Options And Restricted Stock [Member] \| Stock Incentive Plans [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	4,501,434
Performance Stock Units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation costs \| $	$ 9.7
Unrecognized compensation cost weighted average vesting period	1 year 2 months 19 days
Performance Stock Units [Member] \| Stock Incentive Plans [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock reserved for issuance	3,181,537
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation costs \| $	$ 0.7
Unrecognized compensation cost weighted average vesting period	8 months 23 days
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation costs \| $	$ 20.3
Unrecognized compensation cost weighted average vesting period	2 years 10 months 13 days

Leases (Tables)

6 Months Ended

Oct. 31, 2023

Leases

Schedule of lease costs

Schedule of lease costs
	Three Months Ended October 31,				Six Months Ended October 31,
	2023		2022		2023		2022
Operating lease cost	$	1,150	$	1,090	$	2,290	$	2,173
Variable lease cost		424		408		775		797
Short-term lease cost		31		197		67		327
Finance lease costs:
Amortization of right-of-use assets		54		54		108		108
Interest on lease liabilities		25		33		52		66
Total lease cost	$	1,684	$	1,782	$	3,292	$	3,471

Schedule of balance sheet classification of leases


Leases	Classification	October 31, 2023		April 30, 2023
Assets
Operating	Operating lease right-of-use assets	$	41,973	$	42,772
Finance	Property and equipment, net		9,803		2,529
Total leased assets		$	51,776	$	45,301

Liabilities
Current:
Operating	Current portion of operating lease liabilities	$	1,263	$	1,358
Finance	Other current liabilities		1,403		531
Non-current:
Operating	Operating lease liabilities, less current portion		45,036		45,690
Finance	Finance lease liabilities, less current portion		7,840		1,562
Total lease liabilities		$	55,542	$	49,141

Schedule of operating and finance leases


Weighted average remaining lease term (years):
Operating leases	16.2	16.6
Finance leases	6.2	3.7
Weighted average discount rate:
Operating leases	6.0%	6.0%
Finance leases	6.4%	5.3%

Schedule of supplemental cash flow information related to leases


	Six Months Ended October 31,
	2023		2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,149	$	2,063
Operating cash flows from finance leases		52		65
Financing cash flows from finance leases		262		249

Schedule of maturities of lease liabilities


Fiscal Year Ending April 30,	Operating Leases			Finance Leases			Total
2024 (remaining period)	$	1,990		$	982		$	2,972
2025		4,060			1,963			6,023
2026		4,167			1,963			6,130
2027		4,199			1,754			5,953
2028		4,036			1,334			5,370
Thereafter		56,418			3,336			59,754
Total lease payments	$	74,870		$	11,332		$	86,202
Less: imputed interest		(28,571	)		(2,089	)		(30,660	)
Total lease liabilities	$	46,299		$	9,243		$	55,542

Summary of Significant Accounting Policies (Details - Cash) - USD ($) $ in Thousands	Oct. 31, 2023	Apr. 30, 2023	Oct. 31, 2022	Apr. 30, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 31,424	$ 38,542	$ 77,292	$ 126,166
Restricted cash	0	350	350	350
Total cash, cash equivalents and restricted cash	$ 31,424	$ 38,892	$ 77,642	$ 126,516

Net Income (Loss) Per Common Share (Details - Reconciliation of per share) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Numerator
Net income (loss)	$ (9,509)	$ (1,156)	$ (11,602)	$ 408
Denominator
Weighted average basic common shares outstanding	63,149	62,204	62,994	62,054
Effect of dilutive securities:
Stock options	0	0	0	1,294
RSUs, PSUs and ESPP	0	0	0	226
Weighted average dilutive common shares outstanding	63,149	62,204	62,994	63,574
Net income (loss) per share:
Basic	$ (0.15)	$ (0.02)	$ (0.18)	$ 0.01
Diluted	$ (0.15)	$ (0.02)	$ (0.18)	$ 0.01

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2023	Oct. 31, 2022
Income Statement [Abstract]
Revenues	$ 25,395	$ 34,757	$ 63,121	$ 71,449
Cost of revenues	30,060	30,610	63,686	58,185
Gross profit (loss)	(4,665)	4,147	(565)	13,264
Operating expenses:
Selling, general and administrative	6,557	6,831	12,820	13,213
Total operating expenses	6,557	6,831	12,820	13,213
Operating income (loss)	(11,222)	(2,684)	(13,385)	51
Interest expense	(805)	(703)	(1,580)	(1,221)
Other income, net	140	145	398	195
Net loss before income taxes	(11,887)	(3,242)	(14,567)	(975)
Income tax benefit	(2,378)	(2,086)	(2,965)	(1,383)
Net income (loss)	(9,509)	(1,156)	(11,602)	408
Comprehensive income (loss)	$ (9,509)	$ (1,156)	$ (11,602)	$ 408
Net income (loss) per share:
Basic	$ (0.15)	$ (0.02)	$ (0.18)	$ 0.01
Diluted	$ (0.15)	$ (0.02)	$ (0.18)	$ 0.01
Weighted average common shares outstanding:
Basic	63,149	62,204	62,994	62,054
Diluted	63,149	62,204	62,994	63,574